Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Verizon Communications Inc (VZ) Price & Performance

Charles River Laboratories Intl. IncTrade
Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Verizon Communications Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Verizon Communications Inc trades at $42.84 (market cap $177.34B). The key difference: Verizon Communications Inc is far larger — about 15.9× Charles River Laboratories Intl. Inc's market cap, and Verizon Communications Inc pays a 6.66% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLVZ
Market Cap
$11.14B$177.34B
Sector
HealthMedia
52-Week High
$233.60$51.38
52-Week Low
$145.57$38.40
Enterprise Value
$14.00B$364.84B
Volume
22,584,735
Dividend Yield
6.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Verizon Communications Inc

Verizon (VZ) trades at $42.68, up 1.33% today, with a bearish technical signal from moving averages but recent earnings beats. The stock offers a 6.7% dividend yield with a consensus price target of $47.57, indicating 11.5% upside. Revenue grew to $138.19B in 2025, with a net income margin of 12.46%, while debt levels remain elevated at $144B total debt. Recent news highlights competitive threats from SpaceX's Starlink but also new partnerships like the 5G deal with BMW.

Outlook: VZ presents a value opportunity with a low P/E of 10.4 and strong cash flow, but faces significant competitive and debt-related risks. The stock is suitable for income-focused investors seeking defensive yield, though growth is constrained by industry saturation and rising capital expenditures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ